Human leukocyte antigen A*02:01-restricted Epstein-Barr virus latent membrane protein 1 and 2 peptide-major histocompatibility complexes (HLA-A2/EBV LMP1-LMP2 pMHC)

HLA-A*02:01-restricted peptide-MHC complexes presenting Epstein-Barr virus (EBV) Latent Membrane Protein 1 (LMP1) and Latent Membrane Protein 2 (LMP2) epitopes are specialized molecular targets on the surface of EBV-infected cells. These complexes are formed when the host's HLA-A*02:01 molecule presents specific 9-10 amino acid peptides derived from the viral LMP1 or LMP2 proteins to the immune system (Lin et al., 2018, Frontiers in Immunology). Because LMP1 and LMP2 are consistently expressed in EBV-associated Type II and Type III latency malignancies—such as nasopharyngeal carcinoma, Hodgkin lymphoma, and NK/T-cell lymphomas—they serve as highly specific tumor-associated viral antigens (Bollard & Heslop, 2016, Blood). Therapeutic interventions, including TCR-engineered T cells (TCR-T) and TCR-like antibodies, are designed to recognize these specific pMHC configurations to trigger cytotoxic cell death (Choi et al., 2018, Oncotarget). This targeting strategy exploits the viral origin of the peptides to achieve high tumor specificity and minimize damage to non-infected healthy tissues. However, challenges such as HLA downregulation by tumor cells and potential cross-reactivity with similar human self-peptides remain significant considerations in drug development (Smith et al., 2017, Cancer Research).

Other names

HLA-A*02:01/LMP1 complexHLA-A*02:01/LMP2 complexEBV LMP-specific peptide-MHC complexesHLA-A2-restricted EBV epitopesLMP1/2-HLA-A2 complex

Recognition and binding by engineered T-cell receptors (TCRs) or TCR-like antibodies, leading to the activation of cytotoxic immune responses against cells presenting the viral epitopes.